Company Overview: CymaBay

Industry News

13 Nov

CymaBay Therapeutics to Present at Three Investor Conferences

NEWARK, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will provide a corporate overview at the 29th Annual Piper Jaffray Healthcare Conference, the Evercore/ISI 2017...

Read more

1 Nov

CymaBay to Report Third Quarter 2017 Financial Results on Wednesday, November 8

NEWARK, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Wednesday, November 8, 2017 at...

Read more

9 Oct

CymaBay Announces Oral Late-Breaking Presentation of Interim Results from an Ongoing Phase 2 Study of Patients with Primary Biliary Cholangitis at the AASLD 2017 Liver Meeting

– Interim phase 2 study results demonstrate the potential for superior efficacy and better tolerability over existing second-line therapy – CymaBay will also present new clinical research on pruritus, a symptom frequently affecting the quality of life for patients with primary biliary cholangitis – Company will host Post-AASLD Key...

Read more

18 Sep

CymaBay Therapeutics to Present at Two Investor Conferences

NEWARK, Calif., Sept. 18, 2017 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need, today announced that management will provide a corporate overview at the Cantor Fitzgerald Global Healthcare Conference, and the...

Read more

11 Sep

CymaBay Therapeutics Granted EMA Orphan Drug Designation for Seladelpar for the Treatment of Primary Biliary Cholangitis

NEWARK, Calif., Sept. 11, 2017 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need today announced that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on...

Read more

15 Aug

CymaBay Therapeutics Announces the Publication of the Seladelpar Proof-of-Concept Study for Primary Biliary Cholangitis in Lancet Gastroenterology and Hepatology

NEWARK, Calif., Aug. 15, 2017 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that the proof-of-concept study of seladelpar, a potent and selective PPARδ agonist, for the treatment of primary...

Read more

26 Jul

Cymabay Therapeutics

CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was...

Read more

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address